The pharmacists of the Covid-19 maintain the pull in the year of the return to the status quo. Pfizer, Johnson&Johnson (J&J), AstraZeneca and Moderna, companies that develop vaccines against Covid-19, increased their joint profit by 10.5% in 2022 compared to 2021, according to the latest results published by the different companies and collected by PlantTwelve.
The joint profit of J&J, Pfizer, Moderna and AstraZeneca reached 60,968 million dollars in 2022, compared to 55,174 million dollars in 2021. The increase has occurred despite the fact that J&J and Moderna shrank their profit in the last year. For their part, joint sales reached 259,067 million dollars in 2022, which represents an increase of 12.2% compared to a year ago.
Pfizer, the largest company by turnover, has been the great driver of this growth. The company closed 2022 with a profit of 31,372 million dollars, compared to the 21,979 million dollars reached in 2021. The pharma developer of the vaccine against Covid-19 Comirnaty registered a turnover of 100.330 million dollars last year, which translates into an increase of 23% compared to 2021, when the multinational obtained revenues of 81.288 million dollars. The American company became the first pharmaceutical company worldwide with a turnover of more than 100,000 million a year.
The approval of the vaccine for more and more age groups and the booster doses have allowed Pfizer to surpass even the figures of 2013, its previous record, when it earned 22,000 million dollars, boosted by the sale of its subsidiary Zoetis. Comirnaty contributes 37.8 billion dollars to that total, while Paxlovid adds 18.9 billion dollars. In total, both account for more than 56% of the company’s revenue. The vaccine achieves its highest revenues in Europe, while the main market for the pill has been the United States.
Pfizer has been the first pharmaceutical company to exceed 10,000 million revenues a year
For its part, Johnson&Johnson closed 2022 with a profit of 17,941 million dollars, which translates into a decrease of 14.1% compared to the data for 2021. Despite this lower result, by business segments, the division Pharmaceutical, the most important by turnover, entered 52,563 million dollars, 1.7% more.
At the end of 2023, the American multinational will be divided into two listed companies. To do this, the multinational will spin off its consumer and home health division, which will generate sales of 15,000 million dollars this year, according to company forecasts. The group will keep its pharmaceutical and medical device business.
AstraZeneca closed 2022 with a profit of 3,293 million dollarscompared to the 115 million dollars reached in 2021. The company justifies this growth by the boost in the business of its cancer treatments and the effects derived from the integration of the biotech Alexion.
AstraZeneca’s turnover in 2022 was 44,531 million dollars, compared to 37,417 million dollars reached in 2021Therefore, the multinational improved its income by almost 19% in the last year.
Likewise, the income of Evusheld, an AstraZeneca drug that is a combination of two monoclonal antibodies (tixagevimab and cilgavimab) indicated for the passive immunization of patients at risk of contracting Covid-19, went from entering 85 million dollars in 2021 to 2,185 billion dollars in 2022.
AstraZeneca’s Covid-19 drug brought the company revenue of 2,180 million in 2022
Finally, Moderna closed 2022 with a profit of 8,362 million dollars, 31% less than in 2021. Moderna’s total revenues in 2022 were 19,263 million dollars, compared to 18,471 million dollars in 2021. Of this amount In total, product sales were $18.435 million, compared to $17.675 million in 2021.
Although the company expects to enter 5,000 million dollars as a result of its agreements for the advance purchase of vaccines against Covid-19 in the United States, Europe, Japan and other key markets, the biotech company turns its strategy to promote its messenger RNA (RNA) technology to new vaccines against different types of cancers. In fact, the company works hand in hand with Merck in the development of vaccines against skin cancer and both companies hope to start a Phase III study in 2023.
